Pharma deal analysis divides US FTC
The US Federal Trade Commission has approved Bristol-Myers Squibb’s acquisition of Celgene on a party-line vote, but both Democratic commissioners called for the agency to look more broadly at consolidation in the pharmaceutical industry.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.